Amended Current Report Filing (8-k/a)
June 20 2016 - 5:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 17, 2016 (June 10, 2016)
BIOSCRIP, INC.
(Exact name of Registrant as specified in
its charter)
Delaware
|
|
000-28740
|
|
05-0489664
|
(State of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1600 Broadway, Suite 950, Denver, Colorado
|
|
80202
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (720) 697-5200
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
x
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
This Form 8-K/A amends the Current Report on Form 8-K (the
“
Form 8-K
”), dated and filed as of June 16, 2016, with respect to the amendment of the asset purchase agreement,
dated June 11, 2016 (the “
Asset Purchase Agreement
”), by and among BioScrip, Inc., HomeChoice Partners, Inc.,
a Delaware corporation and a wholly owned subsidiary of the Company, HS Infusion Holdings, Inc., a Delaware corporation (“
Home
Solutions
”) and each of the subsidiaries of Home Solutions set forth on the signature pages to the Asset Purchase Agreement.
The purpose of this amendment to the Form 8-K is to replace the version of the First Amendment to the Asset Purchase Agreement
previously filed as
Exhibit 2.1
(the “
First Amendment to the Asset Purchase Agreement
”) to the Form
8-K with the version attached to this Form 8-K/A as
Exhibit 2.1
, which corrects a typographical error in the previously
filed version. Effective upon the filing of this Form 8-K/A,
Exhibit 2.1
of the Form 8-K is replaced and superseded in
its entirety by
Exhibit 2.1
to this Form 8-K/A. Capitalized terms used and not otherwise defined herein shall have the
respective meanings assigned to them in the First Amendment to the Asset Purchase Agreement.
Additional Information and Where to Find It
In connection with the proposed acquisition, the Company will prepare a proxy statement to be filed with the Securities and Exchange
Commission ("SEC"). When completed, a definitive proxy statement and a form of proxy will be mailed to the stockholders
of the Company.
The Company's security holders are urged to read the proxy statement carefully when it becomes available, as
well as any other relevant documents filed by the Company with SEC, because they will contain important information.
The Company's
stockholders will be able to obtain, without charge, a copy of the proxy statement (when available) and other relevant documents
filed with the SEC from the SEC's website at
http://www.sec.gov
. The Company's stockholders will also be able to obtain,
without charge, a copy of the proxy statement and other relevant documents (when available) by directing a request by mail or
telephone to BioScrip, Inc., Attn: Chief Financial Officer, 1600 Broadway, Suite 950, Denver, CO 80202, telephone: (720) 697-5200,
or from the investor relations page on the Company's website at
http://bioscrip.com/overview
.
The Company and its directors and officers may be
deemed to be participants in the solicitation of proxies from the Company's stockholders in connection with the proposed acquisition.
Information about the Company's directors and executive officers and their ownership of the Company's equity interests is set forth
in the proxy statement for the Company's 2016 Annual Meeting of Stockholders, which was filed with the SEC on April 27, 2016. Stockholders
may obtain additional information regarding the interests of the Company and its directors and executive officers in the proposed
acquisition, which may be different than those of the Company's stockholders generally, by reading the proxy statement and other
relevant documents regarding the proposed acquisition when filed with the SEC.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits. See the Exhibit Index which
is hereby incorporated by reference.
.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOSCRIP, INC.
|
|
|
|
|
Date: June 17, 2016
|
/s/ Kathryn M. Stalmack
|
|
|
By: Kathryn M. Stalmack
|
|
|
Senior Vice President, General Counsel and Secretary
|
|
Index to Exhibits
Exhibit Number
|
Description
|
|
|
2.1
|
The First Amendment, dated June 16,
2016, to the Asset Purchase Agreement, dated June 11, 2016, by and among HS Infusion Holdings, Inc., the direct
and indirect subsidiaries of HS Infusion Holdings, Inc. set forth on the signature pages, the Company and HomeChoice
Partners, Inc.
|
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Apr 2024 to May 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From May 2023 to May 2024